|
US3707475A
(en)
|
1970-11-16 |
1972-12-26 |
Pfizer |
Antiinflammatory imidazoles
|
|
DE3029376A1
(de)
|
1980-07-31 |
1982-03-18 |
Nepera Chemical Co. Inc., Harriman, N.Y. |
Verfahren zur herstellung von 2,4,5-tris-pyridylimidazolen
|
|
EP0149884B1
(en)
|
1983-09-09 |
1992-12-16 |
Takeda Chemical Industries, Ltd. |
5-pyridyl-1,3-thiazole derivatives, their production and use
|
|
JP2722586B2
(ja)
|
1989-01-13 |
1998-03-04 |
大正製薬株式会社 |
インドリルイミダゾール誘導体
|
|
JP2808460B2
(ja)
|
1989-11-16 |
1998-10-08 |
大正製薬株式会社 |
イミダゾール誘導体
|
|
US6358932B1
(en)
|
1994-05-31 |
2002-03-19 |
Isis Pharmaceticals, Inc. |
Antisense oligonucleotide inhibition of raf gene expression
|
|
US5717100A
(en)
|
1995-10-06 |
1998-02-10 |
Merck & Co., Inc. |
Substituted imidazoles having anti-cancer and cytokine inhibitory activity
|
|
GB2306108A
(en)
|
1995-10-13 |
1997-04-30 |
Merck & Co Inc |
Treatment of Raf-mediated cancers with imidazole derivatives
|
|
WO1998008845A1
(en)
|
1996-08-27 |
1998-03-05 |
Novartis Ag |
Herbicidal s-substituted 1,2,4,6-thiatriazines
|
|
JP4713698B2
(ja)
|
1997-03-05 |
2011-06-29 |
スージェン， インク． |
疎水性薬剤の処方
|
|
AR012634A1
(es)
|
1997-05-02 |
2000-11-08 |
Sugen Inc |
Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
|
|
GB9711650D0
(en)
|
1997-06-05 |
1997-07-30 |
Pfizer Ltd |
Compounds useful in therapy
|
|
GB9716557D0
(en)
|
1997-08-06 |
1997-10-08 |
Glaxo Group Ltd |
Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
|
|
US6022884A
(en)
|
1997-11-07 |
2000-02-08 |
Amgen Inc. |
Substituted pyridine compounds and methods of use
|
|
US6211177B1
(en)
|
1998-11-24 |
2001-04-03 |
Cell Pathways, Inc. |
Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US6548529B1
(en)
|
1999-04-05 |
2003-04-15 |
Bristol-Myers Squibb Company |
Heterocyclic containing biphenyl aP2 inhibitors and method
|
|
DE60001229T2
(de)
|
1999-04-09 |
2003-10-30 |
Smithkline Beecham Corp., Philadelphia |
Triarylimidazole
|
|
PT1169038E
(pt)
|
1999-04-15 |
2012-10-26 |
Bristol Myers Squibb Co |
Inibidores cíclicos da proteína tirosina cinase
|
|
JP2000302680A
(ja)
|
1999-04-23 |
2000-10-31 |
Takeda Chem Ind Ltd |
脳保護剤
|
|
ES2270867T3
(es)
|
1999-09-23 |
2007-04-16 |
Astrazeneca Ab |
Compuestos de quinazolina terapeuticos.
|
|
HK1050190A1
(zh)
|
1999-11-22 |
2003-06-13 |
Smithkline Beecham Plc |
咪唑衍生物和它们做为raf激酶抑制剂的用途
|
|
WO2001052846A1
(en)
|
2000-01-18 |
2001-07-26 |
Vertex Pharmaceuticals Incorporated |
Gyrase inhibitors and uses thereof
|
|
NZ520628A
(en)
|
2000-01-18 |
2004-05-28 |
Vertex Pharma |
thiazole, oxazole, imdazole or pyrazole substituted pyrazole derivatives useful as treating bacterial infections
|
|
CO5271680A1
(es)
|
2000-02-21 |
2003-04-30 |
Smithkline Beecham Corp |
Compuestos
|
|
GB0005357D0
(en)
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
JP2003525936A
(ja)
|
2000-03-06 |
2003-09-02 |
スミスクライン ビーチャム パブリック リミテッド カンパニー |
Ｒａｆキナーゼ阻害物質としてのイミダゾール誘導体
|
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
|
EP1268474A2
(en)
|
2000-03-30 |
2003-01-02 |
Takeda Chemical Industries, Ltd. |
Substituted 1,3-thiazole compounds, their production and use
|
|
US6608053B2
(en)
|
2000-04-27 |
2003-08-19 |
Yamanouchi Pharmaceutical Co., Ltd. |
Fused heteroaryl derivatives
|
|
MXPA02012314A
(es)
|
2000-06-12 |
2004-09-06 |
Eisai Co Ltd |
Compuestos de 1,2-dihidropiridina, metodo de fabricacion y utilizacion de los mismos.
|
|
CA2416685C
(en)
|
2000-07-19 |
2008-10-07 |
Warner-Lambert Company |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
HUP0400651A2
(hu)
|
2000-11-07 |
2004-06-28 |
Bristol-Myers Squibb Company |
Szerin proteáz inhibitorokként alkalmazható savszármazékok és ezeket tartalmazó gyógyszerkészítmények
|
|
US20040053943A1
(en)
|
2000-11-20 |
2004-03-18 |
Adams Jerry L. |
Novel compounds
|
|
EP1341771A2
(en)
|
2000-11-29 |
2003-09-10 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
WO2002064136A2
(en)
|
2001-01-26 |
2002-08-22 |
Chugai Seiyaku Kabushiki Kaisha |
Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
|
|
WO2002062792A1
(en)
|
2001-02-02 |
2002-08-15 |
Takeda Chemical Industries, Ltd. |
Jnk inhibitor
|
|
WO2002076960A1
(en)
|
2001-03-22 |
2002-10-03 |
Abbott Gmbh & Co. Kg |
Transition metal mediated process
|
|
JP2002338537A
(ja)
|
2001-05-16 |
2002-11-27 |
Mitsubishi Pharma Corp |
アミド化合物およびその医薬用途
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
GB0129260D0
(en)
|
2001-12-06 |
2002-01-23 |
Eisai London Res Lab Ltd |
Pharmaceutical compositions and their uses
|
|
US8299108B2
(en)
|
2002-03-29 |
2012-10-30 |
Novartis Ag |
Substituted benzazoles and methods of their use as inhibitors of raf kinase
|
|
US7071216B2
(en)
|
2002-03-29 |
2006-07-04 |
Chiron Corporation |
Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
|
|
AR039241A1
(es)
|
2002-04-04 |
2005-02-16 |
Biogen Inc |
Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
|
|
HRP20050252A2
(en)
|
2002-09-18 |
2005-10-31 |
Pfizer Products Inc. |
Novel imidazole compounds as transforming growth factor (tfg) inhibitors
|
|
WO2004026863A1
(en)
|
2002-09-18 |
2004-04-01 |
Pfizer Products Inc. |
Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
|
|
US7531553B2
(en)
|
2003-03-21 |
2009-05-12 |
Amgen Inc. |
Heterocyclic compounds and methods of use
|
|
AR045944A1
(es)
|
2003-09-24 |
2005-11-16 |
Novartis Ag |
Derivados de isoquinolina 1.4-disustituidas
|
|
US7449582B2
(en)
|
2003-10-08 |
2008-11-11 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
|
DE602004021838D1
(de)
|
2003-10-16 |
2009-08-13 |
Novartis Vaccines & Diagnostic |
Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
|
|
US8969372B2
(en)
|
2003-11-14 |
2015-03-03 |
Aptose Boisciences Inc. |
Aryl imidazoles and their use as anti-cancer agents
|
|
KR101150077B1
(ko)
|
2004-03-05 |
2012-06-01 |
다이쇼 세이야꾸 가부시끼가이샤 |
티아졸 유도체
|
|
KR100749566B1
(ko)
|
2004-04-21 |
2007-08-16 |
이화여자대학교 산학협력단 |
Ａｌｋ5 및/또는 ａｌｋ4 억제제로 유효한 2-피리딜이치환된 이미다졸 유도체
|
|
WO2005105814A1
(en)
|
2004-04-28 |
2005-11-10 |
Incyte Corporation |
Tetracyclic inhibitors of janus kinases
|
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
|
JP4163738B2
(ja)
|
2004-06-11 |
2008-10-08 |
日本たばこ産業株式会社 |
癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
|
|
US7453002B2
(en)
|
2004-06-15 |
2008-11-18 |
Bristol-Myers Squibb Company |
Five-membered heterocycles useful as serine protease inhibitors
|
|
GB0415364D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415367D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
GB0415365D0
(en)
|
2004-07-09 |
2004-08-11 |
Astrazeneca Ab |
Pyrimidine derivatives
|
|
JP2008511631A
(ja)
|
2004-08-31 |
2008-04-17 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
ＴＧＦ−βインヒビターとしてのピリミジニルイミダゾール
|
|
WO2006038734A1
(en)
|
2004-10-08 |
2006-04-13 |
Astellas Pharma Inc. |
Pyridazinone derivatives cytokines inhibitors
|
|
AU2005295734A1
(en)
|
2004-10-15 |
2006-04-27 |
Biogen Idec Ma Inc. |
Methods of treating vascular injuries
|
|
JP2007246520A
(ja)
|
2006-02-15 |
2007-09-27 |
Takeda Yuichiro |
Ｒａｇｅ阻害剤
|
|
EP2007393B1
(en)
|
2006-04-07 |
2013-08-21 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers
|
|
BRPI0714908B8
(pt)
|
2006-08-08 |
2021-05-25 |
Chugai Pharmaceutical Co Ltd |
derivados de pirimidina como inibidor de pi3k, composição farmacêutica e agente preventivo ou agente terapêutico de uma doença proliferativa que os compreende
|
|
WO2008071605A2
(en)
|
2006-12-15 |
2008-06-19 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
JP5140154B2
(ja)
|
2007-06-27 |
2013-02-06 |
アストラゼネカ・アクチエボラーグ |
ピラジノン誘導体および肺疾患の処置におけるそれらの使用
|
|
AU2008273017C1
(en)
|
2007-06-29 |
2014-02-13 |
Millennium Pharmaceuticals, Inc. |
Heterocyclic compounds useful as Raf kinase inhibitors
|
|
TWI444379B
(zh)
|
2007-06-29 |
2014-07-11 |
Sunesis Pharmaceuticals Inc |
有用於作為Ｒａｆ激酶抑制劑之化合物
|
|
JP2010531850A
(ja)
|
2007-07-02 |
2010-09-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規化合物
|
|
CN101796048A
(zh)
|
2007-07-09 |
2010-08-04 |
阿斯利康(瑞典)有限公司 |
用于治疗增殖病症的三取代的嘧啶衍生物
|
|
MX2010000617A
(es)
|
2007-07-17 |
2010-05-17 |
Plexxikon Inc |
Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
|
|
US8293747B2
(en)
|
2007-07-19 |
2012-10-23 |
Merck Sharp & Dohme Corp. |
Heterocyclic amide compounds as protein kinase inhibitors
|
|
US20110190280A1
(en)
|
2007-08-29 |
2011-08-04 |
George Adjabeng |
Thiazole And Oxazole Kinase Inhibitors
|
|
TW200916458A
(en)
|
2007-09-05 |
2009-04-16 |
Astrazeneca Ab |
Heterocyclic compounds and methods of use thereof
|
|
WO2009047163A1
(en)
|
2007-10-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Methods of treating inflammatory diseases
|
|
TW200940537A
(en)
|
2008-02-26 |
2009-10-01 |
Astrazeneca Ab |
Heterocyclic urea derivatives and methods of use thereof
|
|
US8865732B2
(en)
|
2008-03-21 |
2014-10-21 |
Novartis Ag |
Heterocyclic compounds and uses thereof
|
|
EA201001456A1
(ru)
|
2008-03-21 |
2011-06-30 |
Новартис Аг |
Новые гетероциклические соединения и их применение
|
|
UA103319C2
(en)
|
2008-05-06 |
2013-10-10 |
Глаксосмитклайн Ллк |
Thiazole- and oxazole-benzene sulfonamide compounds
|
|
EA201001847A1
(ru)
|
2008-06-11 |
2011-08-30 |
Айрм Ллк |
Соединения и композиции, применяемые для лечения малярии
|
|
AU2009273197B2
(en)
|
2008-07-24 |
2014-01-16 |
Nerviano Medical Sciences S.R.L. |
3,4-diarylpyrazoles as protein kinase inhibitors
|
|
KR101353857B1
(ko)
|
2008-08-22 |
2014-01-21 |
노파르티스 아게 |
Ｃｄｋ 억제제로서 피롤로피리미딘 화합물
|
|
WO2010048149A2
(en)
|
2008-10-20 |
2010-04-29 |
Kalypsys, Inc. |
Heterocyclic modulators of gpr119 for treatment of disease
|
|
ES2921576T3
(es)
|
2008-12-19 |
2022-08-29 |
Vertex Pharma |
Compuestos útiles como inhibidores de la quinasa ATR
|
|
US8242260B2
(en)
|
2009-08-28 |
2012-08-14 |
Novartis Ag |
Compounds and compositions as protein kinase inhibitors
|
|
CN102471310A
(zh)
|
2009-09-04 |
2012-05-23 |
诺瓦提斯公司 |
用于治疗增生性疾病的联吡啶化合物
|
|
EP2498608A4
(en)
|
2009-11-10 |
2013-04-24 |
Glaxosmithkline Llc |
BENZOLSULFONAMIDE THIAZOL AND OXAZOLE COMPOUNDS
|
|
PL2520575T3
(pl)
|
2009-12-28 |
2017-05-31 |
General Incorporated Association Pharma Valley Project Supporting Organization |
Związek 1,3,4-oksadiazolo-2-karboksyamidowy
|
|
US9315491B2
(en)
|
2009-12-28 |
2016-04-19 |
Development Center For Biotechnology |
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
KR20110123657A
(ko)
|
2010-05-07 |
2011-11-15 |
에스케이케미칼주식회사 |
피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
|
|
US20130096149A1
(en)
|
2010-06-25 |
2013-04-18 |
Novartis Ag |
Heteroaryl compounds and compositions as protein kinase inhibitors
|
|
WO2012027438A1
(en)
|
2010-08-26 |
2012-03-01 |
Glaxosmithkline Llc |
Pharmaceutical combination of a vegfr inhibitor and a mek inhibitor useful for treating cancer
|
|
CN101993415B
(zh)
|
2010-09-15 |
2013-08-14 |
北京韩美药品有限公司 |
作为Hedgehog通路抑制剂的化合物以及包含该化合物的药物组合物及其应用
|
|
AR083797A1
(es)
|
2010-11-10 |
2013-03-20 |
Novartis Ag |
Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
|
|
PL2672967T3
(pl)
|
2011-02-07 |
2019-04-30 |
Plexxikon Inc |
Związki i sposoby modulacji kinaz i wskazania ku temu
|
|
WO2013022766A1
(en)
|
2011-08-05 |
2013-02-14 |
Flynn Gary A |
Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
|
|
JP6134319B2
(ja)
|
2011-09-01 |
2017-05-24 |
ノバルティス アーゲー |
ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
|
|
EP2758379B1
(en)
|
2011-09-21 |
2016-10-19 |
Cellzome Limited |
Urea and carbamate derivatives of 2-morpholino-1,3,5-triazine as mTOR inhibitors for the treatment of immunological or proliferative diseases
|
|
WO2013164769A1
(en)
|
2012-05-02 |
2013-11-07 |
Lupin Limited |
Substituted pyridine compounds as crac modulators
|
|
EA201492005A1
(ru)
|
2012-05-15 |
2015-04-30 |
Новартис Аг |
Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
|
|
WO2014008214A1
(en)
|
2012-07-02 |
2014-01-09 |
Biogen Idec Ma Inc. |
Biaryl-containing compounds as inverse agonists of ror-gamma receptors
|
|
AR091876A1
(es)
*
|
2012-07-26 |
2015-03-04 |
Novartis Ag |
Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
|
|
EP2882440B1
(en)
*
|
2012-08-07 |
2019-02-27 |
Novartis AG |
Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
|
|
AU2013313050A1
(en)
|
2012-09-04 |
2015-03-26 |
Novartis Ag |
Method of adjuvant cancer treatment
|
|
MX372736B
(es)
|
2012-09-28 |
2020-06-19 |
Cancer Research Tech Ltd |
Inhibidores de azaquinazolina de la proteina quinasa c atipica.
|
|
EP2903613B1
(en)
|
2012-10-08 |
2017-11-22 |
Merck Sharp & Dohme Corp. |
Pyrazole derivatives useful as inhibitors of irak4 activity
|
|
WO2014097125A1
(en)
*
|
2012-12-20 |
2014-06-26 |
Novartis Ag |
Pharmaceutical combination comprising binimetinib
|
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
|
CN112641787A
(zh)
*
|
2013-03-21 |
2021-04-13 |
诺华股份有限公司 |
包含B-Raf抑制剂和第二抑制剂的组合疗法
|
|
PE20161073A1
(es)
*
|
2013-11-01 |
2016-10-30 |
Novartis Ag |
Amino-heteroaril-benzamidas como inhibidores de cinasa
|
|
WO2015095819A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Biomed Valley Discoveries, Inc. |
Cancer treatment using combinations of erk and raf inhibitors
|
|
WO2016038583A1
(en)
|
2014-09-12 |
2016-03-17 |
Novartis Ag |
Compounds and compositions as kinase inhibitors
|
|
UY36294A
(es)
|
2014-09-12 |
2016-04-29 |
Novartis Ag |
Compuestos y composiciones como inhibidores de quinasa
|
|
JP6636014B2
(ja)
|
2014-09-12 |
2020-01-29 |
ノバルティス アーゲー |
Ｒａｆキナーゼ阻害剤としての化合物および組成物
|
|
WO2016115376A1
(en)
|
2015-01-14 |
2016-07-21 |
The Regents Of The University Of California |
Detection and treatment of double drug resistant melanomas
|
|
CA2991805A1
(en)
|
2015-07-10 |
2017-01-19 |
Genmab A/S |
Axl-specific antibody-drug conjugates for cancer treatment
|
|
CN108348514A
(zh)
*
|
2015-08-28 |
2018-07-31 |
诺华股份有限公司 |
含pi3k抑制剂alpelisib和cdk4/6抑制剂ribociclib的药物组合以及其在治疗/预防癌症中的应用
|
|
JP2018525425A
(ja)
|
2015-08-28 |
2018-09-06 |
ノバルティス アーゲー |
がんを治療または予防するためのリボシクリブとダブラフェニブの組み合わせ
|
|
MX387795B
(es)
*
|
2016-06-03 |
2025-03-19 |
Array Biopharma Inc |
Combinaciones farmaceuticas.
|
|
RU2018146886A
(ru)
*
|
2016-06-10 |
2020-07-10 |
Новартис Аг |
Пути терапевтического применения ингибитора c-raf
|
|
WO2018051306A1
(en)
|
2016-09-19 |
2018-03-22 |
Novartis Ag |
Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
|
|
US11590133B2
(en)
|
2016-12-11 |
2023-02-28 |
Memorial Sloan Kettering Cancer Center |
Methods and compositions for treatment of BRAF mutant cancers
|
|
KR20240032157A
(ko)
|
2017-05-02 |
2024-03-08 |
노파르티스 아게 |
병용 요법
|
|
AU2018269982B2
(en)
|
2017-05-16 |
2024-06-13 |
Biomed Valley Discoveries, Inc. |
Compositions and methods for treating cancer with atypical BRAF mutations
|
|
TW202023556A
(zh)
|
2018-08-27 |
2020-07-01 |
美商庫拉腫瘤技術股份有限公司 |
以mapk路徑抑制劑治療腺癌
|
|
AU2019407159A1
(en)
|
2018-12-20 |
2021-07-15 |
Novartis Ag |
Combination therapy with a Raf inhibitor and a CKD4/6 inhibitor for use in the treatment of cancer
|
|
MX2021013817A
(es)
|
2019-05-13 |
2021-12-14 |
Novartis Ag |
Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
|
|
TW202140029A
(zh)
|
2020-02-18 |
2021-11-01 |
瑞士商諾華公司 |
用於治療ｂｒａｆ突變型ｎｓｃｌｃ的包含ｒａｆ抑制劑之治療組合
|
|
CN115551509A
(zh)
|
2020-05-12 |
2022-12-30 |
诺华股份有限公司 |
包含craf抑制剂的治疗组合
|